- Home
- COYA
as 10-29-2025 9:37am EST
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 107.0M | IPO Year: | 2022 |
| Target Price: | $16.20 | AVG Volume (30 days): | 274.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.65 - $10.24 | Next Earning Date: | 11-06-2025 |
| Revenue: | $423,452 | Revenue Growth: | -95.57% |
| Revenue Growth (this year): | 40.8% | Revenue Growth (next year): | -86.75% |
Latest Coya Therapeutics Inc. News
COYA Breaking Stock News: Dive into COYA Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Investors Digest September Inflation Report, Lifting US Equity Futures Pre-Bell
MT Newswires
5 days ago
Coya Therapeutics Prices $20 Million Public Offering of Common Stock; Shares Fall Pre-Bell
MT Newswires
5 days ago
Top Premarket Decliners
Business Wire
5 days ago
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
MT Newswires
5 days ago
Coya Therapeutics Plans Public Stock Offering
Simply Wall St.
5 days ago
Coya Therapeutics (COYA) Valuation in Focus After Follow-On Equity Offering Announced
Business Wire
6 days ago
Coya Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire
22 days ago
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
Compare COYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COYA Coya Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.